These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Influence of Glycosylated Hemoglobin on the Efficacy of Ranibizumab for Diabetic Macular Edema: A Post Hoc Analysis of the RIDE/RISE Trials. Bansal AS; Khurana RN; Wieland MR; Wang PW; Van Everen SA; Tuomi L Ophthalmology; 2015 Aug; 122(8):1573-9. PubMed ID: 26050541 [TBL] [Abstract][Full Text] [Related]
3. Improvement of diabetic retinopathy with intravitreal Ranibizumab. Kernt M; Cserhati S; Seidensticker F; Liegl R; Kampik A; Neubauer A; Ulbig MW; Reznicek L Diabetes Res Clin Pract; 2013 Apr; 100(1):e11-3. PubMed ID: 23391744 [TBL] [Abstract][Full Text] [Related]
5. Comparing aflibercept, bevacizumab, and ranibizumab for DME: analysis of DRCR Protocol T. Wykoff CC; Hariprasad SM Ophthalmic Surg Lasers Imaging Retina; 2015 Mar; 46(3):302-5. PubMed ID: 25835307 [No Abstract] [Full Text] [Related]
6. Visual outcome after intravitreal bevacizumab depends on the optical coherence tomographic patterns of patients with diffuse diabetic macular edema. Shimura M; Yasuda K; Yasuda M; Nakazawa T Retina; 2013 Apr; 33(4):740-7. PubMed ID: 23222391 [TBL] [Abstract][Full Text] [Related]
7. A prospective randomized trial of intravitreal bevacizumab versus ranibizumab for the management of diabetic macular edema. Nepomuceno AB; Takaki E; Paes de Almeida FP; Peroni R; Cardillo JA; Siqueira RC; Scott IU; Messias A; Jorge R Am J Ophthalmol; 2013 Sep; 156(3):502-510.e2. PubMed ID: 23795985 [TBL] [Abstract][Full Text] [Related]
8. Effects of intravitreal ranibizumab on retinal hard exudate in diabetic macular edema: findings from the RIDE and RISE phase III clinical trials. Domalpally A; Ip MS; Ehrlich JS Ophthalmology; 2015 Apr; 122(4):779-86. PubMed ID: 25601535 [TBL] [Abstract][Full Text] [Related]
9. Peripheral retinal function assessed with 30-Hz flicker seems to improve after treatment with Lucentis in patients with diabetic macular oedema. Holm K; Schroeder M; Lövestam Adrian M Doc Ophthalmol; 2015 Aug; 131(1):43-51. PubMed ID: 25773362 [TBL] [Abstract][Full Text] [Related]
10. Factors associated with changes in visual acuity and central subfield thickness at 1 year after treatment for diabetic macular edema with ranibizumab. Bressler SB; Qin H; Beck RW; Chalam KV; Kim JE; Melia M; Wells JA; Arch Ophthalmol; 2012 Sep; 130(9):1153-61. PubMed ID: 22965591 [TBL] [Abstract][Full Text] [Related]
12. Association of retinal vessel calibre and visual outcome in eyes with diabetic macular oedema treated with ranibizumab. Moradi A; Sepah YJ; Ibrahim MA; Sophie R; Moazez C; Bittencourt MG; Annam RE; Hanout M; Liu H; Ferraz D; Do DV; Nguyen QD; Eye (Lond); 2014 Nov; 28(11):1315-20. PubMed ID: 25145456 [TBL] [Abstract][Full Text] [Related]
13. Functional and morphological changes in diabetic macular edema over the course of anti-vascular endothelial growth factor treatment. Reznicek L; Cserhati S; Seidensticker F; Liegl R; Kampik A; Ulbig M; Neubauer AS; Kernt M Acta Ophthalmol; 2013 Nov; 91(7):e529-36. PubMed ID: 23647578 [TBL] [Abstract][Full Text] [Related]
14. Effect of macular ischemia on intravitreal ranibizumab treatment for diabetic macular edema. Douvali M; Chatziralli IP; Theodossiadis PG; Chatzistefanou KI; Giannakaki E; Rouvas AA Ophthalmologica; 2014; 232(3):136-43. PubMed ID: 25171753 [TBL] [Abstract][Full Text] [Related]
15. Comparison of a single intravitreal injection of bevacizumab versus triamcinolone acetonide as primary treatment for diffuse diabetic macular oedema. Penha FM; Maia M; Cardillo JA; Arevalo JF; Wu L; Rodriguez FJ; Berrocal MH; Farah ME; Acta Ophthalmol; 2012 Mar; 90(2):e160-1. PubMed ID: 21470386 [No Abstract] [Full Text] [Related]
16. DRCR Protocol-T: Reconciling 1- and 2-Year Data for Managing Diabetic Macular Edema. Wykoff CC; Hariprasad SM Ophthalmic Surg Lasers Imaging Retina; 2016 Apr; 47(4):308-12. PubMed ID: 27065368 [No Abstract] [Full Text] [Related]
17. Intravitreal triamcinolone acetonide versus combined intravitreal bevacizumab and dexamethasone in diffuse diabetic macular oedema. Sheth S; Rush R; Natarajan S; Gillies M Clin Exp Ophthalmol; 2011; 39(7):673-81. PubMed ID: 22452685 [TBL] [Abstract][Full Text] [Related]
18. Resolution of diabetic papillopathy after a single intravitreal injection of ranibizumab. Willerslev A; Munch IC; Larsen M Acta Ophthalmol; 2012 Aug; 90(5):e407-9. PubMed ID: 22268957 [No Abstract] [Full Text] [Related]
19. Short-term efficacy of intravitreal triamcinolone acetonide for bevacizumab-resistant diabetic macular oedema. Kim JH; Lee TG; Lew YJ Acta Ophthalmol; 2015 Mar; 93(2):e178-9. PubMed ID: 25043969 [No Abstract] [Full Text] [Related]
20. Degree of decrease in central retinal thickness predicts visual acuity response to intravitreal ranibizumab in diabetic macular edema. Santos AR; Gomes SC; Figueira J; Nunes S; Lobo CL; Cunha-Vaz JG Ophthalmologica; 2014; 231(1):16-22. PubMed ID: 24280908 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]